About ▼ Careers Internship MedBlog Contact us
English (US) ▼
Medindia
LOGIN REGISTER
Medindia

FDA Approves SynGenX-1000 Cord Blood Processing Platform

by Savitha C Muppala on Jul 20 2013 12:23 PM

FDA Approves SynGenX-1000 Cord Blood Processing Platform
A company that makes products for extracting stem cells from a variety of sources, SynGen Inc., of Sacramento, CA, has received the FDA nod for its SynGenX-1000 platform.
The SynGenX-1000 platform is capable of harvesting stem cells from umbilical cord blood.

About Stem Cells
About Stem Cells
Encyclopedia section of medindia gives general info about Stem Cells
Philip Coelho, CEO of SynGen, said “This ‘next generation’ SynGenX™-1000 System improves the recovery of stem and progenitor cells from cord blood units, which should increase the number of clinical grade units available for transplantation. The CryoPRO-2™ simplifies the cryopreservation workflow for cord blood bank personnel and provides a medical record of the process. The SynGen™ DataTrak software captures the data associated with processing each cord blood unit for the blood bank’s records.”



Source-Medindia
About Cord Blood
About Cord Blood
Encyclopedia section of medindia gives general info about Cord Blood
Bone Marrow Aspiration and Biopsy-Indications-Common Sites-Performed-Risks-FAQs
Bone Marrow Aspiration and Biopsy-Indications-Common Sites-Performed-Risks-FAQs
Bone marrow biopsy and aspiration is the removal of some bone marrow tissue for diagnosis and management of cancers of blood cells and multiple myeloma.
Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia (CLL) is one of the most common types of adult leukemia and is considered as one of the ‘good cancers’.

Recommended Readings
Latest Medical Gadgets
View All
Advertisement